STRO vs TARA

Sutro Biopharma, Inc. vs Protara Therapeutics, Inc. — Valuation Comparison 2026

STRO

Biotechnology
Sutro Biopharma, Inc.
Quality
5.6
out of 10
Value Trap
24
SAFE
Price
$29.63
Last close
Models
8/13
Active
VS

TARA

Biotechnology
Protara Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$4.75
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType STRO Fair ValueSTRO Upside TARA Fair ValueTARA Upside
Bayesian DCF Intrinsic $7.89 -73.4% $1.39 -70.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $4.73 -84.0% $2.67 -43.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for STRO vs TARA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

STRO vs TARA — Which Stock Is More Undervalued?

STRO scores higher with a 5.6/10 quality rating vs TARA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Sutro Biopharma, Inc. (STRO) and Protara Therapeutics, Inc. (TARA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

STRO currently trades at $29.63 with a QOC of 5.6/10, while TARA trades at $4.75 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).